Arrowhead Pharmaceuticals Inc (ARWR) concluded trading on Wednesday at a closing price of $11.35, with 3.77 million shares of worth about $42.82 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -41.37% during that period and on April 16, 2025 the price saw a loss of about -11.81%. Currently the company’s common shares owned by public are about 125.57M shares, out of which, 114.16M shares are available for trading.
Stock saw a price change of -3.81% in past 5 days and over the past one month there was a price change of -24.81%. Year-to-date (YTD), ARWR shares are showing a performance of -39.63% which decreased to -52.73% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.57 but also hit the highest price of $30.41 during that period. The average intraday trading volume for Arrowhead Pharmaceuticals Inc shares is 2.05 million. The stock is currently trading -10.48% below its 20-day simple moving average (SMA20), while that difference is down -28.91% for SMA50 and it goes to -44.77% lower than SMA200.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) currently have 125.57M outstanding shares and institutions hold larger chunk of about 70.69% of that.
The stock has a current market capitalization of $1.56B and its 3Y-monthly beta is at 0.90. It has posted earnings per share of -$5.15 in the same period. It has Quick Ratio of 6.09 while making debt-to-equity ratio of 16.58. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ARWR, volatility over the week remained 9.60% while standing at 8.89% over the month.
Stock’s fiscal year EPS is expected to rise by 41.08% while it is estimated to decrease by -25.21% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on June 05, 2024 offering a Neutral rating for the stock and assigned a target price of $31 to it. Coverage by BofA Securities stated Arrowhead Pharmaceuticals Inc (ARWR) stock as a Buy in their note to investors on December 04, 2023, suggesting a price target of $29 for the stock. Stock get a Market perform rating from SVB Securities on May 12, 2023.
